Literature DB >> 25973301

VEGF-C-VEGFR3/Flt4 axis regulates mammary tumor growth and metastasis in an autocrine manner.

Michelle L Varney1, Rakesh K Singh1.   

Abstract

PURPOSE: Lymphangiogenic factors, such as vascular endothelial growth factor-C (VEGF-C) and VEGFC-D, and their receptor, VEGF receptor-3 (VEGFR3), play a pivotal role in the promotion of metastasis to regional lymph nodes. In the present study we explored the role of VEGF-C as an autocrine growth factor for breast cancer cells.
METHODS: We examined the expression of VEGF-C and VEGFR3 in mammary tumor cells lines and examined whether blocking the VEGF-C-VEGFR3/Flt4 pathway using a VEGFR3 antagonist would inhibit proliferation of mammary tumor cells resulting in a decrease in tumor growth and metastasis.
RESULTS: We report expression of VEGF-C and its receptor VEGFR3 by mammary tumor cells, and their association with aggressiveness. Inhibition of VEGF-C-VEGFR3/Flt4 in mammary tumor cells decreased their proliferation and survival. Mammary tumor bearing mice treated with a VEGFR3 antagonist showed a significant decrease in tumor growth and the extent of spontaneous and experimental lung metastases.
CONCLUSION: These findings demonstrate the VEGF-C-VEGFR3/Flt4 autocrine signaling pathway regulates mammary tumor cell survival and proliferation and that neutralization of VEGFR3 signaling might lead to development of a novel therapeutic approach for malignant breast cancer.

Entities:  

Keywords:  Breast cancer; lymphangiogenesis; metastasis; vascular endothelial growth factor receptor-3; vascular endothelial growth factor-C

Year:  2015        PMID: 25973301      PMCID: PMC4396036     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  17 in total

1.  MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo.

Authors:  Vladimir Kirkin; Wilko Thiele; Petra Baumann; Ralph Mazitschek; Katrin Rohde; Guido Fellbrich; Herbert Weich; Johannes Waltenberger; Athanassios Giannis; Jonathan P Sleeman
Journal:  Int J Cancer       Date:  2004-12-20       Impact factor: 7.396

2.  Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival.

Authors:  Zhengtang Chen; Michelle L Varney; Matthew W Backora; Kenneth Cowan; Joyce C Solheim; James E Talmadge; Rakesh K Singh
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance.

Authors:  Marissa J Stanton; Samikshan Dutta; Heyu Zhang; Navatha S Polavaram; Alexey A Leontovich; Pia Hönscheid; Frank A Sinicrope; Donald J Tindall; Michael H Muders; Kaustubh Datta
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

4.  Cyclooxygenase-2 expression is associated with VEGF-C and lymph node metastases in gastric cancer patients.

Authors:  J Zhang; J Ji; F Yuan; L Zhu; C Yan; Y-Y Yu; B-Y Liu; Z-G Zhu; Y-Z Lin
Journal:  Biomed Pharmacother       Date:  2005-10       Impact factor: 6.529

5.  RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Authors:  Yukuan Feng; Jing Hu; Jing Ma; Kejian Feng; Xiaoli Zhang; Shucai Yang; Wei Wang; Jianguo Zhang; Yafang Zhang
Journal:  Eur J Cancer       Date:  2011-06-15       Impact factor: 9.162

6.  Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.

Authors:  Christopher A Garces; Elena V Kurenova; Vita M Golubovskaya; William G Cance
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

7.  The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.

Authors:  Jen-Liang Su; Pan-Chyr Yang; Jin-Yuan Shih; Ching-Yao Yang; Lin-Hung Wei; Chang-Yao Hsieh; Chia-Hung Chou; Yung-Ming Jeng; Ming-Yang Wang; King-Jen Chang; Mien-Chie Hung; Min-Liang Kuo
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.

Authors:  Jian Feng Wang; Xuefeng Zhang; Jerome E Groopman
Journal:  J Biol Chem       Date:  2004-04-21       Impact factor: 5.157

9.  Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.

Authors:  Elena V Kurenova; Darrell L Hunt; Dihua He; Ann D Fu; Nicole A Massoll; Vita M Golubovskaya; Christopher A Garces; William G Cance
Journal:  Cell Cycle       Date:  2009-07-23       Impact factor: 4.534

10.  Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis.

Authors:  R A A Mohammed; A Green; S El-Shikh; E C Paish; I O Ellis; S G Martin
Journal:  Br J Cancer       Date:  2007-03-13       Impact factor: 7.640

View more
  20 in total

1.  VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner.

Authors:  Seiji Shigetomi; Yorihisa Imanishi; Katsushi Shibata; Nobuya Sakai; Koji Sakamoto; Ryoichi Fujii; Noboru Habu; Kuninori Otsuka; Yoichiro Sato; Yoshihiro Watanabe; Masayuki Shimoda; Kaori Kameyama; Hiroyuki Ozawa; Toshiki Tomita; Kaoru Ogawa
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

2.  An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth.

Authors:  Yan Chen; Xin Liu; Cong Guo Jin; Yong Chun Zhou; Roya Navab; Kristine Raaby Jakobsen; Xiao Qun Chen; Jia Li; Ting Ting Li; Lu Luo; Xi Cai Wang
Journal:  Tumour Biol       Date:  2015-09-16

Review 3.  Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies.

Authors:  Christopher Montemagno; Frédéric Luciano; Gilles Pagès
Journal:  Methods Mol Biol       Date:  2022

4.  Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.

Authors:  Leya Groysman; Lindsey Carlsen; Kelsey E Huntington; Wen H Shen; Lanlan Zhou; Wafik S El-Deiry
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

5.  Soluble vascular endothelial growth factor receptors 2 (sVEGFR-2) and 3 (sVEGFR-3) and breast cancer risk in the Swedish Mammography Cohort.

Authors:  Holly Harris; Alicja Wolk; Anders Larsson; Marie-Paule Vasson; Samar Basu
Journal:  Int J Mol Epidemiol Genet       Date:  2016-03-23

6.  Proline-Rich Homeodomain protein (PRH/HHEX) is a suppressor of breast tumour growth.

Authors:  R M Kershaw; D Roberts; J Wragg; A M Shaaban; E Humphreys; J Halsall; L Price; R Bicknell; K Gaston; P-S Jayaraman
Journal:  Oncogenesis       Date:  2017-06-12       Impact factor: 7.485

7.  WISP-1 promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-300 in human oral squamous cell carcinoma cells.

Authors:  Ching-Chia Lin; Po-Chun Chen; Ming-Yu Lein; Ching-Wen Tsao; Chiu-Chen Huang; Shih-Wei Wang; Chih-Hsin Tang; Kwong-Chung Tung
Journal:  Oncotarget       Date:  2016-03-01

8.  Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of miR-381 in human chondrosarcoma cells.

Authors:  Huey-En Tzeng; An-Chen Chang; Chun-Hao Tsai; Shih-Wei Wang; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2016-06-21

Review 9.  Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

Authors:  Qinlian Jiao; Lei Bi; Yidan Ren; Shuliang Song; Qin Wang; Yun-Shan Wang
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

10.  Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer.

Authors:  Zhiwei Liu; Troy J Kemp; Yu-Tang Gao; Amanda Corbel; Emma E McGee; Juan Carlos Roa; Bingsheng Wang; Juan Carlos Araya; Ming-Chang Shen; Asif Rashid; Ann W Hsing; Allan Hildesheim; Catterina Ferreccio; Ruth M Pfeiffer; Ligia A Pinto; Jill Koshiol
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.